Teva Investigational Site 172 — Commack, New York

Teva Investigational Site 172 is a clinical research site located in Commack, New York, United States 11725.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

Teva Investigational Site 172 has participated in 1 clinical trials.

Therapeutic areas: Tardive Dyskinesia.

Sponsors: Auspex Pharmaceuticals, Inc..

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Teva Investigational Site 172?

Teva Investigational Site 172 has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Teva Investigational Site 172 conducted?

Teva Investigational Site 172 has 1 clinical trials on record. Their work covers Tardive Dyskinesia.

Is Teva Investigational Site 172 accredited by Crixeo Health?

Teva Investigational Site 172 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Teva Investigational Site 172?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.